ReOxy therapy
ReOxy therapy, also known as Intermittent Hypoxia Hyperoxia Therapy or IHHT, is a treatment method based on the positive cell protection molecular mechanisms that are triggered in response to changes in oxygen levels.
ReOxy Procedure
ReOxy therapy procedure consists of repeated short-term hypoxia (9-15% O2) periods, interrupted by brief periods of recovery (30-35% O2). The gas mixtures are supplied to a patient via facial mask, lasting about 45 min in total per treatment session. During the procedure, the patient's vital signs are continuously monitored, such as blood oxygen saturation (SpO2), pulse and respiration rate, perfusion index and pulse variability index.
The hypoxic load is dosed strictly individually by adjusting the targeted SpO2, as measured during a preliminary hypoxic test. A standard hypoxia tolerance test (max. 10 min of 11% O2 gas mixture) is performed to determine the treatment session parameters by monitoring changes in blood oxygen saturation and heart rate in response to hypoxia.
Features
Although the physiological responses in creating hypoxia are mediated through the same HIF-mediated signalling pathways, different intensity and duration of hypoxic exposure leads to turning “on” and “off” different mechanisms at different times, which makes the final effects different: from no response at low intensity until the formation of a physiological adaptive response with a correctly selected “dose” of hypoxia or the development of negative consequences with a further increase in the stimulus disproportionate to the body’s capabilities.[1][2].
Until recently, it was the level of oxygen concentration in the inhaled gas mixture and the duration of hypoxic intervals that were the main parameters determining the level of hypoxic load[3]. However, a number of authors have shown that different patients with equal parameters of external hypoxic exposure may experience different levels of endogenous hypoxic load, as evidenced by differences in changes in SpO2 levels [4][5]. This is due to the fact that the body's adaptive response to hypoxia is determined both by the current physiological state of the body and by individual sensitivity to oxygen deficiency, which largely depends on the genotype, age, presence of concomitant diseases, medication, and other factors[6]. Therefore, the level of hypoxic load should be selected strictly individually, based solely on the functional capabilities of the organism of each patient at the time of the procedure.
ReOxy therapy is the only IHT method where the hypoxic load parameters (FiO2, minimal SpO2 level, maximal pulse rate, time to minimal SpO2 level, recovery time to baseline SpO2, min – max pulse rate levels, individual side-effects) are calculated individually for each patient based on the functional indicators of the body, assessed during preliminary testing.
SRT technology (self-regulating procedure) is a unique intelligent technology for automated analysis of the relationship between medical data received from a patient and the intensity of exposure to a therapeutic factor for the subsequent calculation of individual procedure parameters.
The built-in patented algorithm for adapting therapy to the capabilities of the body of each individual patient is implemented using artificial intelligence technologies, when the device “independently” makes a decision based on an instant analysis of a large amount of data. In the case of a method where hypoxic exposures are the main factor, it is the personalized calculation of the hypoxic exposure dose that plays a fundamental role. If the hypoxic load is insufficient, the procedure will not be effective; excessive hypoxic load is dangerous for the patient and can cause serious disturbances in the body.
Applications/Effects
The effectiveness and safety of the ReOxy-therapy method has been evaluated in a number of clinical studies. At present, efficacy has been shown for the rehabilitation of patients with cardiovascular, chronic bronchopulmonary diseases and metabolic disorders [7][8][9][10][11]
References
- ↑ Sullivan, Jerome L.; Bailey, Damian Miles; Zacharski, Leo R. (2010-04-13). "Letter by Sullivan et al Regarding Article, "Lower Mortality from Coronary Heart Disease and Stroke at Higher Altitudes in Switzerland"". Circulation. 121 (14): e376. doi:10.1161/CIR.0b013e3181dab7d5. ISSN 0009-7322. PMID 20385958.
- ↑ Verges, Samuel; Chacaroun, Samarmar; Godin-Ribuot, Diane; Baillieul, Sébastien (2015-06-22). "Hypoxic Conditioning as a New Therapeutic Modality". Frontiers in Pediatrics. 3: 58. doi:10.3389/fped.2015.00058. ISSN 2296-2360. PMC 4476260. PMID 26157787.
- ↑ Navarrete-Opazo, Angela; Mitchell, Gordon S. (2014-11-15). "Therapeutic potential of intermittent hypoxia: a matter of dose". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 307 (10): R1181–R1197. doi:10.1152/ajpregu.00208.2014. ISSN 0363-6119. PMC 4315448. PMID 25231353.
- ↑ Törpel, Alexander; Peter, Beate; Hamacher, Dennis; Schega, Lutz (May 2019). "Dose–response relationship of intermittent normobaric hypoxia to stimulate erythropoietin in the context of health promotion in young and old people". European Journal of Applied Physiology. 119 (5): 1065–1074. doi:10.1007/s00421-019-04096-8. ISSN 1439-6319. PMID 30756167. Unknown parameter
|s2cid=ignored (help) - ↑ Harshman, Sean W; Geier, Brian A; Fan, Maomian; Rinehardt, Sage; Watts, Brandy S; Drummond, Leslie A; Preti, George; Phillips, Jeffrey B; Ott, Darrin K; Grigsby, Claude C (2015-10-27). "The identification of hypoxia biomarkers from exhaled breath under normobaric conditions". Journal of Breath Research. 9 (4): 047103. doi:10.1088/1752-7155/9/4/047103. ISSN 1752-7163. PMID 26505091. Unknown parameter
|s2cid=ignored (help) - ↑ Кривощеков, С. Г.; Балиоз, Н. В.; Некипелова, Н. В.; Капилевич, Л. В. (2014). "Возрастные, гендерные и индивидуально-типологические особенности реагирования на острое гипоксическое воздействие". Физиология человека (in русский). 40 (6): 34–45. doi:10.7868/S013116461406006X. ISSN 0131-1646.
- ↑ Glazachev, Oleg S.; Kryzhanovskaya, Svetlana Yu; Zapara, Maxim A.; Dudnik, Elena N.; Samartseva, Vlada G.; Susta, Davide (2021). "Safety and Efficacy of Intermittent Hypoxia Conditioning as a New Rehabilitation/ Secondary Prevention Strategy for Patients with Cardiovascular Diseases: A Systematic Review and Meta-analysis". Current Cardiology Reviews. 17 (6): 12–23. doi:10.2174/1573403x17666210514005235. PMC 8950503 Check
|pmc=value (help). PMID 33992064 Check|pmid=value (help). - ↑ Muangritdech, Nattha; Hamlin, Michael J.; Sawanyawisuth, Kittisak; Prajumwongs, Piya; Saengjan, Wisutthida; Wonnabussapawich, Preetiwat; Manimmanakorn, Nuttaset; Manimmanakorn, Apiwan (August 2020). "Hypoxic training improves blood pressure, nitric oxide and hypoxia-inducible factor-1 alpha in hypertensive patients". European Journal of Applied Physiology. 120 (8): 1815–1826. doi:10.1007/s00421-020-04410-9. ISSN 1439-6319. PMID 32524226 Check
|pmid=value (help). Unknown parameter|s2cid=ignored (help) - ↑ Glazachev, O. S.; Zvenigorodskaia, L. A.; Dudnik, E. N.; Iartseva, L. A.; Mishchenkova, T. V.; Platonenko, A. V.; Spirina, G. K. (2010). "[Interval hypoxic-hyperoxic training in the treatment of the metabolic syndrome]". Eksperimental'naia i Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology (7): 51–56. ISSN 1682-8658. PMID 21033083.
- ↑ Bestavashvili, Afina; Glazachev, Oleg; Bestavashvili, Alexander; Suvorov, Alexander; Zhang, Yong; Zhang, Xinliang; Rozhkov, Andrey; Kuznetsova, Natalia; Pavlov, Chavdar; Glushenkov, Dmitriy; Kopylov, Philippe (March 2022). "Intermittent Hypoxic-Hyperoxic Exposures Effects in Patients with Metabolic Syndrome: Correction of Cardiovascular and Metabolic Profile". Biomedicines. 10 (3): 566. doi:10.3390/biomedicines10030566. ISSN 2227-9059. PMC 8945352 Check
|pmc=value (help). PMID 35327372 Check|pmid=value (help). - ↑ Serebrovska, Tetiana V.; Portnychenko, Alla G.; Portnichenko, Vladimir I.; Xi, Lei; Egorov, Egor; Antoniuk-Shcheglova, Ivanna; Naskalova, Svitlana; Shatylo, Valeriy B. (March 2019). "Effects of intermittent hypoxia training on leukocyte pyruvate dehydrogenase kinase 1 (PDK-1) mRNA expression and blood insulin level in prediabetes patients". European Journal of Applied Physiology. 119 (3): 813–823. doi:10.1007/s00421-019-04072-2. ISSN 1439-6319. PMID 30701312. Unknown parameter
|s2cid=ignored (help)
This article "ReOxy therapy" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ReOxy therapy. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
